A prospective pilot study comparing combined intravitreal ranibizumab and half-fluence photodynamic therapy with ranibizumab monotherapy in the treatment of neovascular age-related macular degeneration

Patrick D Williams1 Texas Retina Associates, Dallas, TX

David Callanan1 Texas Retina Associates, Dallas, TX

Wayne Solley1 Texas Retina Associates, Dallas, TX

Robert L Avery2 California Retina Consultants and Research Foundation, Santa Barbara, CA

Dante J Pieramici2 California Retina Consultants and Research Foundation, Santa Barbara, CA

Tom Aaberg3 Retinal Associates, Grand Rapids, MI, USACorrespondence[email protected]

Pages 1519-1525 | Published online: 17 Sep 2012

Cite this article

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

References

BrownDMKaiserPKMichelsMRanibizumab versus verteporfin for neovascular age-related macular degenerationN Engl J Med20063551432144417021319
PubMed Web of Science ®Google Scholar
RosenfeldPJBrownDMHeierJSRanibizumab for neovascular age-related macular degenerationN Engl J Med20063551419143117021318
PubMed Web of Science ®Google Scholar
FintakDRShahGKBlinderKJIncidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumabRetina2008281395139918827737
PubMed Web of Science ®Google Scholar
RegilloCDBrownDMAbrahamPRandomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1Am J Ophthalmol200814523924818222192
PubMed Web of Science ®Google Scholar
FungAELalwaniGARosenfeldPJAn optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degenerationAm J Ophthalmol200714356658317386270
PubMed Web of Science ®Google Scholar
LalwaniGARosenfeldPJFungAEA variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO StudyAm J Ophthalmol2009148435819376495
PubMed Web of Science ®Google Scholar
Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study GroupPhotodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials – TAP reportArch Ophthalmol19991171329134510532441
PubMed Web of Science ®Google Scholar
Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study GroupPhotodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials – TAP report 2Arch Ophthalmol200111919820711176980
PubMed Web of Science ®Google Scholar
ArnoldJJBlinderKJBresslerNMAcute severe visual acuity decrease after photodynamic therapy with verteporfin: case reports from randomized clinical trials – TAP and VIP report no 3Am J Ophthalmol200413768369615059708
PubMed Web of Science ®Google Scholar
AzabMBoyerDSBresslerNMVerteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trialArch Ophthalmol200512344845715824216
PubMed Web of Science ®Google Scholar
Schmidt-ErfurthUWolfSPROTECT Study GroupSame day administration of verteporfin and ranibizumab 0.5 mg in patients with choroidal neovascluarization due to age related macular degenerationBr J Ophthalmol2008921628163518772178
PubMed Web of Science ®Google Scholar
RudniskyCJLiuCNgMWeisETennantMTIntravitreal bevacizumab alone versus combined verteporfin photodynamic therapy and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration: visual acuity after 1 year of follow-upRetina20103054855420386095
PubMed Web of Science ®Google Scholar
KaiserPKBoyerDSRegistry of Visudyne AMD Therapy Writing CommitteeVerteporf in photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degenerationOphthalmology200911674775519243834
PubMed Web of Science ®Google Scholar
SmithBTDhallaMSShahGKBlinderKJRyanEHJrMittraRAIntravitreal injection of bevacizumab combined with verteporfin photodynamic therapy for choroidal neovascularization in age-related macular degenerationRetina20082867568118463509
PubMed Web of Science ®Google Scholar
AveryRlPieramiciDJRabenaMDCastellarinAANasirMAGiustMJIntravitreal bevacizumab (Avastin) for neovascularization age-related macular degenerationOphthalmology200611336337216458968
PubMed Web of Science ®Google Scholar
AugustinATriple therapy for age-related macular degenerationRetina200929S8S1119553805
PubMed Web of Science ®Google Scholar
YipPPWooCFTangHHHoCKTriple therapy for neovascular age-related macular degeneration using single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinoloneBr J Ophthalmol20099375475819273471
PubMed Web of Science ®Google Scholar
AugustinAJPulsSOffermannITriple therapy for choroidal neovascularization due to age-related macular degeneration: verteporfin PDT, bevacizumab, and dexamethasoneRetina20072713314017290193
PubMed Web of Science ®Google Scholar

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

A prospective pilot study comparing combined intravitreal ranibizumab and half-fluence photodynamic therapy with ranibizumab monotherapy in the treatment of neovascular age-related macular degeneration

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

A prospective pilot study comparing combined intravitreal ranibizumab and half-fluence photodynamic therapy with ranibizumab monotherapy in the treatment of neovascular age-related macular degeneration

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date